Израел - Енглески - Ministry of Health

neopharm (israel) 1996 ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - multiple myelomabortezomib fresenius kabi is indicated for the treatment of adult patients with multiple myeloma.mantle cell lymphomabortezomib fresenius kabi for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib fresenius kabi in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Малта - Енглески - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - concentrate for solution for infusion - cabazitaxel 20 mg/ml - antineoplastic agents

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cabazitaxel - concentrate for solution for infusion - cabazitaxel

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - fludarabine phosphate -

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - temozolomide -

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - busulfan -

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - temozolomide -

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - letrozole -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - topotecan hydrochloride, quantity: 4.346 mg - injection, powder for - excipient ingredients: mannitol; tartaric acid; hydrochloric acid; sodium hydroxide - topotecan is indicated as single agent therapy for the treatment of patients with: - small cell lung carcinoma, after failure of first line chemotherapy. - metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dibasic sodium phosphate dodecahydrate - metronidazole intravenous infusion is indicated:,(a) for treatment of anaerobic infections in patients for whom oral administration is not possible.,(b) where immediate anti-anaerobic chemotherapy is required.,(c) where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.,note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.